Liquidia (NASDAQ:LQDA) Shares Gap Down After Earnings Miss

Shares of Liquidia Corporation (NASDAQ:LQDA) gapped down before the market opened on Thursday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $34.38, but opened at $32.00. Liquidia shares last traded at $33.32, with a volume of 946,647 shares changing hands.

The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.18). Liquidia had a negative net margin of 43.53% and a negative return on equity of 237.79%. The company had revenue of $92.02 million during the quarter. The company’s revenue was up 3072.4% on a year-over-year basis.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on LQDA shares. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Liquidia in a report on Thursday. Needham & Company LLC lifted their price target on Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a research note on Thursday. Wall Street Zen downgraded Liquidia from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. BTIG Research upped their price objective on shares of Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Zacks Research cut shares of Liquidia from a “strong-buy” rating to a “hold” rating in a report on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Insider Buying and Selling

In related news, insider Rajeev Saggar sold 21,142 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $791,345.06. Following the transaction, the insider directly owned 176,883 shares of the company’s stock, valued at approximately $6,620,730.69. The trade was a 10.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Roger Jeffs sold 66,610 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $2,493,212.30. Following the completion of the sale, the chief executive officer directly owned 1,037,528 shares of the company’s stock, valued at approximately $38,834,673.04. This represents a 6.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 212,534 shares of company stock valued at $7,964,719. 26.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently bought and sold shares of the business. Farallon Capital Management LLC increased its holdings in shares of Liquidia by 1.1% in the 4th quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock valued at $298,547,000 after purchasing an additional 90,400 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Liquidia by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after purchasing an additional 52,671 shares during the period. Opaleye Management Inc. grew its position in Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after purchasing an additional 215,000 shares in the last quarter. Caprock Group LLC increased its stake in Liquidia by 9.3% in the 4th quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock valued at $61,527,000 after buying an additional 151,832 shares during the period. Finally, TCG Crossover Management LLC purchased a new stake in Liquidia in the 3rd quarter worth approximately $38,887,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Stock Up 4.4%

The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. The business’s 50 day simple moving average is $37.10 and its 200-day simple moving average is $30.89. The company has a market cap of $3.13 billion, a price-to-earnings ratio of -43.41, a price-to-earnings-growth ratio of 0.60 and a beta of 0.52.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).